Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onco-Innovations Ltd. ( (TSE:ONCO) ) has issued an announcement.
Onco-Innovations Limited has entered into a services agreement with Redwood AI Inc. to advance the development of its Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. This collaboration aims to enhance Onco’s drug development capabilities by utilizing Redwood AI’s AI-driven chemistry tools, which can improve synthesis efficiency, compound design, and expand the pipeline of viable analogs. The partnership is part of Onco’s strategy to progress towards First-in-Human studies, potentially accelerating their timeline towards clinical trials and reinforcing their technical capabilities at a crucial preclinical phase.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company focuses on the prevention and treatment of cancer through pioneering research and innovative solutions, with an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 109,300
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.